Updated on 11 August 2026
CODI - Robot-Assisted Echocardiography
CEO at Cobionix
Canada
About
CODI is a clinician-guided robotic platform for cardiac ultrasound (transthoracic echocardiography). A collaborative robot arm, directed by the sonographer through a haptic controller, performs the physically demanding parts of the scan while the clinician retains full diagnostic control. This targets two pressing problems in echocardiography: a global shortage of sonographers and high rates of work-related musculoskeletal injury, which CODI reduces by cutting repetitive scanning force on the operator by up to 90%. CODI is designed to increase echo throughput by roughly 20% per sonographer and to help injured staff return to full duties. The platform holds ISO 13485 and IEC 60601 certification and is classified as a Class I device under the UK UKCA framework. It is in active clinical evaluation with NHS staff at University Hospital Southampton, where all four standard TTE views have been achieved and sonographers trained in under eight hours. Cobionix is raising a USD 20 million Series A to expand multi-site UK clinical studies and prepare for commercial scale-up.
Project Location
- Canada
Project Website
www.cobionix.com
Project Format
- Private Project
Go Global Project
- Yes
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Investment / Financing Discussion
Main Project Sector
- Technology
Technology
- Health Technology
- Medical Technology
Total Project Value
- 10,000,001 to 25,000,000 USD
Investment Capital Required
- 10,000,001 to 25,000,000 USD
Interested Format of Cooperation
- Minority Shareholdings
- Direct Equity Investment
Preferred Financing Model
- Equity
Type(s) of Last Financing Round of the project (if Applicable)
- Venture Capital (VC)
Return on Investment
To be discussed (Equity, Series A)
Main Service(s) Required
- Financial Services
Financial Services
- Private Equity & Venture Capital
- Investment Banking
Attached files
Similar opportunities
Project
AI enabled Acceleration of Preclinical Biologic Drug Development
- No
- Yes
- Equity
- Bio-Tech
- Technology
- Private Project
- Equity (private)
- Financial Services
- Partner Identification
- Direct Equity Investment
- 10,000,001 to 25,000,000 USD
- Private Equity & Venture Capital
Kingsley Leung
Chairman & Co-founder at Great Bay Bio Limited
China (Hong Kong)
Project
Novel Platinum-Based Drug (HJ-550 )
- Yes
- Yes
- Debt
- Equity
- Bio-Tech
- Technology
- Joint Venture
- Private Project
- Convertible Loan
- Equity (private)
- Financial Services
- Investment Banking
- Professional Services
- Mergers & Acquisition
- 500,001 to 1,000,000 USD
- Direct Equity Investment
- Institutional Investment
- 10,000,001 to 25,000,000 USD
- Private Equity & Venture Capital
- Investment / Financing Discussion
Haiyang Wang
CEO at Shanghai Haiju Biotechnology Co., Ltd.
China
Project
World-leading Elastic Textile-PCB
- No
- Yes
- IoT
- Equity
- Technology
- Private Project
- Venture Capital (VC)
- Professional Services
- Partner Identification
- Direct Equity Investment
- Intelligent Manufacturing
- 1,000,001 to 2,500,000 USD
- 10,000,001 to 25,000,000 USD
Dong Wang
CEO at Easenory Technology Limited
China (Hong Kong)